Sign in
Taking people in United StatesNo phase

Hepatic Lipid Metabolism-Alcohol Use Disorder

Key facts

Who runs it
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Where
Bethesda, United StatesSee the site
Trial code
Status
Recruiting
People taking part
25 people, planned
Started
5 Oct 2026
Expected to end
30 Nov 2029
Type of study
Observational
Treatments tested
  • Liver biopsy
Record updated
8 October 2026

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who cannot take part

  • Existing use of cholesterol lowering medications including statins, fibrates, or other similar medications used for the purposes of treating hyperlipidemia
  • Existing diagnosis of hyperlipidemia or essential hypertension
  • Those with evidence of severe alcoholic hepatitis with a Maddrey s Discriminant Function > 32
  • Those with other chronic liver diseases including chronic hepatitis B (positive hepatitis B surface Ag on admission), hepatitis C (positive hepatitis C RNA), or autoimmune hepatitis (clinical diagnosis based on high titer of positive ANA and or anti smooth muscle Ab and a history of autoimmune disease)
  • HIV infection
  • Hemoglobin A1c >= 6.5%
  • Contraindication or inability to perform a liver biopsy; Participants with coagulopathy (PT/PTT values that are prolonged (Bullet) 3 seconds from the upper limit of the normal, including treatment with oral and parenteral anticoagulants), thrombocytopenia (< 70,000), abnormal bleeding time or platelet dysfunction. Antiplatelet agents taken for cardiovascular prevention will not exclude participants, unless they cannot be stopped safely for the performance of a liver biopsy; Hemoglobin level < 11 g/dL; Inability to provide informed consent
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Pregnancy
  • Waist to hip ratio: >=0.90 in males, >=0.85 in females

Other criteria

  • INCLUSION CRITERIA:; In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Any individual >=18 years of age who is enrolled in 14-AA-0181 and is seeking inpatient treatment
  • Vibration Controlled Elastography parameters with initial CAP of >295dB/m

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Alcohol use disorder

This trial is currently available in United States.

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: NIH Clinical Center Office of Patient Recruitment (OPR)Taking people

About the trial

What the trial wants to find out

Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the steatosis has resolved. The hepatic transcriptome will be compared,

The group in the trial

  • Liver biopsy

    All participants in the study will undergo liver biopsies

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Mechanisms in Hepatic Lipid Metabolism in Alcohol Use Disorder: From Genomics, Transcriptomics to Metabolomics
Criteria questions
Built from NCT07191561, who can take part
Record updated
8 October 2026